6 Psychedelic Clinical Trials That Could Have A Major Impact On The Way We Address Mental HealthPsyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, PPsyched Wellness Is Laser Focused On Uncovering The Medical Properties Associated With MuscimolField Trip Health Has Its Sights Set On Jamaica To Spearhead Future R&D InitiativesPure Extracts Submits Multiple SKUs to Health Canada for ApprovalTryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post ListingNuminus Wellness Is Making Major Headway On Its MDMA TrialsPsyched Wellness Closes $6,603,000 Bought Deal Private PlacementMind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with PsychedelicsTryp Therapeutics Completes $2 Million Strategic FinancingCybin Inc. Is Focused On Taking A Quantitative Approach To Tackling DepressionTryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing ProgramTryp Therapeutics Appoints Dr. Joel Castellanos as Clinical AdvisorField Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica3 Functional Mushroom Leaders Investors Need To Be WatchingTryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer MillerNuminus Wellness Completes Acquisition of Montreal-based Mindspace WellbeingTryp Therapeutics Announces Strategic Investment of $2,000,000Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching
Back

MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

Jan 7, 2021 • 8:12 AM EST
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce the closing of a non-brokered private placement offering by the Company (the “Offering) of an aggregate of 8,000,000 common shares (the “Common Shares“) at a price of CDN$0.30 per Common Share for aggregate gross proceeds of CDN$2.4 million.

“Society is experiencing a significant shift towards alternate treatments for mental illness and this investment lays the foundation for our continued research and ultimate development of novel neuro-pharmaceutical compounds derived from psilocybin and other psychedelic agents,” stated Dr. Lyle Oberg, MYND’s Chief Executive Officer. “We are incredibly excited to complete our initial financing round which provides us with a clear path forward towards achieving our scientific and developmental goals in advance of public listing in Q1 of 2021,” continued Dr. Oberg.

The Company intends to use the proceeds of the Offering to advance MYND’s research, working capital, general operating expenses and public listing costs.

“This initial financing provides my team with significant runway to expand on our already significant IP Portfolio with the ultimate goal of developing novel drugs and delivery methods utilizing psilocybin and other related compounds to treat major depressive disorder,” stated Dr. Wilfred Jefferies, MYND’s Chief Science Officer. “To be granted one of the first Health Canada licenses for psilocybin research provides a unique opportunity for drug discovery, and I look forward to advancing our research throughout the various stages of R&D towards Health Canada and FDA regulatory submissions in the future,” continued Dr. Jefferies.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

ABOUT MYND LIFE SCIENCES

MYND Life Science Inc. is a leading life sciences company focussed on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Forward-Looking Information

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.   

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

SOURCE Mynd Life Sciences Inc.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link